Olapar
Olapar is Olaparib, an oral PARP inhibitor. It is indicated for BRCA-mutated and other homologous recombination deficient ovarian, breast, pancreatic, and prostate cancers and works by blocking DNA repair pathways and promoting synthetic lethality in susceptible tumors.
Features
| Product Name | Olapar |
| Generic Name | Olaparib |
| Formulation | Tablet |
| Available Pack Size | 4X6's, 7X4's |
| Available Strength | 100 mg, 150 mg |